Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2021 Jun 29;27(16):4557–4565. doi: 10.1158/1078-0432.CCR-21-0585

Table 2.

Summary of adverse events (AE) possibly, probably, or definitely related to the study drug

Adverse event Grade 1 Grade 2 Grade 3 Total (%)
Diarrhea 0 0 1 1 (5%)
Fatigue 0 1 0 1 (5%)
Joints pain 0 1 0 1 (5%)
Myalgia 0 1 0 1 (5%)
Pruritus 6 0 0 6 (30%)
Maculo-papular rash 3 0 0 3 (15%)
Hypothyroidism 0 1 0 1 (5%)